Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis

Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic is...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gamal Badra, Imam Waked, Carlo Selmi, Saleh M. Saleh, Ahmed El-Shaarawy, Mahmoud Lotfy
Format:	Article
Language:	English
Published:	Wiley 2006-01-01
Series:	Clinical and Developmental Immunology
Online Access:	http://dx.doi.org/10.1080/17402520600557867
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Treatment of chronic hepatitis С (genotype 6) in patients with contraindications to interferon-α
by: D. A. Lioznov, et al.
Published: (2016-02-01)

The Role of Anti-Interferon-α Autoantibodies in Severe COVID-19: Implications for Vaccination Prioritization
by: Xin Rong Lim, et al.
Published: (2025-07-01)

Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4
by: Olfat Shaker, et al.
Published: (2013-01-01)

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study
by: Javier Milara, et al.
Published: (2015-01-01)

Distribution and genotyping of hepatitis C virus (HCV) infection in Gansu province, China
by: Qiajun Du, et al.
Published: (2024-03-01)

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6
by: D. A. Lioznov, et al.
Published: (2017-04-01)

HCV and HBV genotypes: vital in the progression of HCV/ HBV co-infection
by: Yasmin Badshah, et al.
Published: (2025-01-01)

The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
by: Ying-Chou Huang, et al.
Published: (2021-01-01)

Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin
by: Refaat Sadeq, et al.
Published: (2013-11-01)

A Comparative Evaluation of the Chemiluminescence Immunoassay and ELISA for the Detection of Islet Autoantibodies in Type 1 Diabetes
by: Elisa Danese, et al.
Published: (2025-07-01)

Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin
by: Yu. V. Lobzin, et al.
Published: (2014-09-01)

Islet autoantibodies and residual beta-cell function in children with type 1 diabetes depending on age of manifestation
by: E. M. Romanenkova, et al.
Published: (2023-07-01)

Refractory nontuberculous mycobacterial infection and potential hidden immunodeficiency related to RAG mutation and production of anti-interferon-α autoantibodies: a case report
by: Xiaona Liang, et al.
Published: (2025-04-01)

Pustular reaction in adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies
by: Narachai Julanon, et al.
Published: (2025-08-01)

The Seropositivity Rate of Human Cytomegalovirus [Hcmv] Among Hepatitis B Virus [Hbv] Patients, Hepatitis C Virus [Hcv] Patients, and Blood Donors in Diyala Province
by: Dhaffir Hashim Steer, et al.
Published: (2024-01-01)

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection
by: N. D. Yuschuk, et al.
Published: (2009-02-01)

Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.
by: Nicasio Mancini, et al.
Published: (2009-12-01)

C-peptide levels and the prevalence of islets autoantibodies in children with type 1 diabetes mellitus with different duration of the disease
by: E. M. Romanenkova, et al.
Published: (2022-05-01)

Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C
by: N. B. Kovaleva
Published: (2014-08-01)

Variety of genotypes of a HCV virus and outcomes of chronic hepatitis C: results 5 summer supervision in the territory of the Kirov region
by: S. V. Baramzina, et al.
Published: (2014-09-01)

Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: A prospective study in children.
by: Ezio Bonifacio, et al.
Published: (2018-04-01)

Analytical and Biological Variables Influencing Quantitative Hepatitis C Virus (HCV) Measurement in HIV-HCV Coinfection
by: Curtis Cooper, et al.
Published: (2006-01-01)

Detection of autoantibodies against Interferon Type I in patients with autochthonous West Nile Virus encephalitis
by: Jan Braune, et al.
Published: (2025-10-01)

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
by: Evangelista Sagnelli, et al.
Published: (2012-01-01)

Sequence variation of the HVR1 region of Hepatitis C virus in response to interferon-α and ribavirin treatment
by: Ahmed Ali Al-Qahtani, et al.
Published: (2011-05-01)

Psychometric Validation of the Hepatitis C Symptom and Impact Questionnaire (HCV-SIQv4) in a Diverse Sample of Adults with Chronic Hepatitis C Virus Infection Treated with an Interferon-free Simeprevir-containing Regimen
by: Andrew Trigg, et al.
Published: (2019-02-01)

Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis
by: Maria De Santis, et al.
Published: (2024-09-01)

PECULIARITIES OF THE III TYPE INTERFERON GENES’ POLYMORPHISM IN HCV PATIENTS ON THE CROSS-BORDER REGIONS OF RUSSIA AND MONGOLIA
by: I. V. Malov, et al.
Published: (2017-10-01)

Correction: Serum IgE in the clinical features and disease outcomes of anti-interferon-γ autoantibodies syndrome
by: Ni Chen, et al.
Published: (2025-03-01)

Case Report: Anti-interferon-γ autoantibodies in an adolescent with disseminated Talaromyces marneffei and mycobacterial co-infections
by: Bingkun Li, et al.
Published: (2025-02-01)

The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-α Therapy for Chronic Hepatitis C
by: Huy A. Tran, et al.
Published: (2009-01-01)

Extrahepatic Manifestations and Autoantibodies in Patients with Hepatitis C Virus Infection
by: Takashi Himoto, et al.
Published: (2012-01-01)

HCV non-1b genotypes in injecting drug users from Romania
by: Simona Ruta, et al.
Published: (2016-05-01)

Diagnostic value of islet autoantibody assays practised in Russia. 1. Classic immunofluorescence islet cell antibody assay, immunoradiometric glutamic acid decarboxylase antibody assay, and ELISA tyrosine phosphatase antibody and insulin antibody assays
by: Alexei V. Timofeev, et al.
Published: (2016-11-01)

Commentary on “Intra‐islet α‐cell Gs signaling promotes glucagon release”
by: Tadahiro Kitamura
Published: (2024-12-01)

The level of expression of miR-196a in patients with chronic viral hepatitis C with the first genotype of HCV according to previous experience of antiviral therapy.
by: L. R. Shostakovych-Koretskaya, et al.
Published: (2020-07-01)

Case of the HCV-associated immune thrombocytopenia in patient with chronic hepatitis C
by: Yu. Yu. Ryabokon
Published: (2012-04-01)

Ethnicity and Spontaneous Clearance of Hepatitis C in HIV-HCV Coinfected Patients
by: Lil Miedzinski, et al.
Published: (2008-01-01)

Investigation of Hepatitis C (HCV) Virus Epidemiology in the Capital City of Türkiye
by: Fatih Mehmet Akıllı
Published: (2024-12-01)

IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?
by: Rabia Deniz, et al.
Published: (2024-07-01)